Skip to main content
Name of Scheme

Hepatitis B Virus core protein vaccines: pathway to precision treatment

External Deadline

Internal Deadline


[Licensing negotiation in progress]

[Invitation for Expression of Interest- Deadline: 8 Oct 2026]

The Technology

Food allergy is a global health issue affecting up to 10% of the general population and its prevalence is significantly increasing. Allergen-specific immunotherapy (AIT) is the only causative treatment. Conventional AIT protocol is a prolonged procedure, by which incrementally increasing doses of the initiating allergen are given for years for immune modulation. However, current studied AITs have significant efficacy limitations to develop sustained unresponsiveness, not to mention long-term remission of the disease. The associated side effects and long treatment course also hinder patient adherence and increase the cost of therapy. There is thus a pressing need to develop alternative approaches to mitigate side effects and enhance efficacy of AIT for food allergy.

Our team has constructed a Hepatitis B virus core protein (HBcAg) virus-like particle (VLP) with a “plug-and-display” system for tailor-making AIT vaccine to achieve precision treatment of food allergy. HBcAg is a nano-carrier inducing strong humoral and cellular immune responses. With the successful production of this HBcAg VLP in our laboratory, our team, for the first time, constructed HBcAg-polypeptide vaccines of shrimp tropomyosin. We showed that the vaccines are capable of inducing blocking IgG antibodies and protect against shrimp allergy. This first-ever plug-and-display HBcAg system will serve as prototype of personalized vaccine for food allergy treatment.

Commercialization

The technology is now available for licensing on an exclusive basis.  In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development.  In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society.  Previous or existing business involvement and experience in this area is a plus.

This invitation for expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.

Name of Scheme

Hepatitis B Virus core protein vaccines: pathway to precision treatment

Description

[Licensing negotiation in progress]

[Invitation for Expression of Interest- Deadline: 8 Oct 2026]

The Technology

Food allergy is a global health issue affecting up to 10% of the general population and its prevalence is significantly increasing. Allergen-specific immunotherapy (AIT) is the only causative treatment. Conventional AIT protocol is a prolonged procedure, by which incrementally increasing doses of the initiating allergen are given for years for immune modulation. However, current studied AITs have significant efficacy limitations to develop sustained unresponsiveness, not to mention long-term remission of the disease. The associated side effects and long treatment course also hinder patient adherence and increase the cost of therapy. There is thus a pressing need to develop alternative approaches to mitigate side effects and enhance efficacy of AIT for food allergy.

Our team has constructed a Hepatitis B virus core protein (HBcAg) virus-like particle (VLP) with a “plug-and-display” system for tailor-making AIT vaccine to achieve precision treatment of food allergy. HBcAg is a nano-carrier inducing strong humoral and cellular immune responses. With the successful production of this HBcAg VLP in our laboratory, our team, for the first time, constructed HBcAg-polypeptide vaccines of shrimp tropomyosin. We showed that the vaccines are capable of inducing blocking IgG antibodies and protect against shrimp allergy. This first-ever plug-and-display HBcAg system will serve as prototype of personalized vaccine for food allergy treatment.

Commercialization

The technology is now available for licensing on an exclusive basis.  In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development.  In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society.  Previous or existing business involvement and experience in this area is a plus.

This invitation for expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.

Category

N/A

For inquiries about licensing opportunity, contact

Mr. Paul Cheung

Knowledge Transfer Office

This email address is being protected from spambots. You need JavaScript enabled to view it.

Inventors

Prof. WAI Yee Yan Christine

Keywords

N/A